Pankaj Jethwani, MD, MBA

Dr. Pankaj Jethwani is Managing Partner at W Health Ventures and CEO at 2070 Health. The two organizations found and fund disruptive technology-enabled healthcare companies in India and the US. W Health’s current portfolio of 15 companies serves over 25 million patients globally. He is also the Co-founder and Board Member at The Breakfast Revolution (TBR), a non-profit organization focused on addressing childhood malnutrition in India via evidence-based school nutrition programs. TBR’s nutrition programs work with over 400 schools and pre-schools, and have served over 60 million meals since inception. Dr. Jethwani has been involved in improving healthcare delivery in several care settings in the US and India as an operator, physician leader, management consultant, and investor.

Dr. Jethwani started his career as a Primary Care Physician in Mumbai’s JJ Group of Hospitals. Through this experience, he witnessed first-hand the gaps in health care delivery in Government clinics and hospitals in India. Motivated to bring about reform in this system, he joined The Boston Consulting Group in India where he helped shape BCG’s work with Government agencies to improve delivery of healthcare at scale. Later, Dr. Jethwani worked at Iora Health, a Boston-based primary care company serving patients on Medicare. The company was acquired by One Medical for $2.1 billion.

Currently, Dr. Jethwani leads W Health Ventures in its unique strategy of building generational healthcare companies from scratch in India and the US. He serves on the Boards of companies including Wysa, Mylo, BeatO, Nivaan, Everhope Oncology, Careforce, and 2070 Health.

Pankaj received an MBBS from Maharashtra University of Health Sciences, India and received an MBA from The Wharton School of the University of Pennsylvania.

Ajay Mahipal, MBA

Ajay Mahipal is the Co-founder & General Partner at HealthKois, India’s leading Healthcare Innovation and Impact Fund with over US$ 300 Million in Assets Under Management (AUM).

Ajay is a highly active investor, focusing on high-growth, innovative companies across Health-Tech, Biopharma, MedTech, Healthcare Delivery, and Climate Health. He is recognized for his leadership in building India’s foremost Healthcare AI portfolio, reflecting a strong emphasis on AI-driven healthcare models. His mission is to impact a billion lives through the HealthKois platform by backing exceptional entrepreneurs and nurturing transformative models that solve for affordability, accessibility, and quality of care. He currently serves on the Boards of cutting-edge companies including Qure.ai, Wysa, ekincare, Carepal, Beta Drugs, and BeatO.

With over 21 years of experience spanning Investment Management, Corporate Finance, Corporate Strategy, and Investment Banking, Ajay has a deep and diverse operational background. Previously, he led the CURRAE Healthtech Fund (India's first dedicated early-stage Healthtech Fund) and chaired the Board of Directors for the Amazon & Patni Group JV. His career history includes leadership roles at Patni Family Office, E&Y, American Express, Elara Capital, and Pepsi.

As a respected thought leader in the sector, he co-authored a seminal report on ‘Healthcare Innovation in India’ with Bain & Company. He regularly publishes articles on innovative healthcare models in leading publications and speaks at preeminent global forums, including the World Economic Forum (New York), GPC and BioAsia.

Ajay is a recipient of the prestigious “40 under 40 Award” for best Alternate Investment Professionals. He holds a Chartered Accountant qualification and an MBA from the Indian Institute of Management (IIM), having graduated from Shri Ram College of Commerce (SRCC).

Ketan Patel, MD, MBA

Ketan Patel is a Managing Partner with F-Prime and has worked in the healthcare sector as an investor, consultant, and physician. Prior to joining F-Prime in 2007, Dr. Patel advised biopharmaceutical and medical device companies on brand strategy, clinical development plans, and business development activities in the corporate consulting division of Leerink Swann & Company. Dr. Patel served as a physician at the VA Boston Healthcare System and at Weill Cornell Medical Center-New York Presbyterian Hospital and Memorial-Sloan Kettering Cancer Center where he completed his internal medicine training.

Dr. Patel focuses on investing in therapeutics and medical device companies and has served on the Board of Directors of ABK Biomedical, Aclaris Therapeutics (NASDAQ:ACRS), Avalyn Pharma, Avivomed, Bicara Therapeutics (NASDAQ: BCAX), Caplin Steriles, Comanche Biopharma, Enzene Biosciences, Eywa Pharma, Ivenix (acquired by Fresenius Kabi), Laurus Labs (NSE:LAURUSLABS), Medwell Ventures, Menlo Therapeutics (NASDAQ:MNLO), NextWave Pharmaceuticals (acquired by Pfizer), NFlection Therapeutics, Pediatrix Therapeutics, Rallybio (NASDAQ:RLYB), and Vicept Therapeutics (acquired by Allergan).

Dr. Patel is a graduate of Tufts University School of Medicine, where he received both his MD and MBA as part of that institution’s Healthcare Management Program and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his undergraduate studies in biology and economics with highest honors at Rutgers University.